TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing ...

LONDON - GSK plc (LSE/NYSE:LON: GSK), in collaboration with iTeos Therapeutics, Inc., announced today the termination of their joint development program for belrestotug, an investigational anti-TIGIT ...

iTeos and GSK terminate belrestotug program after GALAXIES Lung-201 results fail to show significant progression-free survival improvements.

WATERTOWN, Mass. and GOSSELIES, Belgium - iTeos Therapeutics, Inc. (NASDAQ: ITOS), a biopharmaceutical company with a market capitalization of $265 million, and its partner GSK have decided to ...

LONDON - GSK plc (LSE/NYSE:GSK), in collaboration with iTeos Therapeutics, Inc., announced today the termination of their joint development program for belrestotug, an investigational anti-TIGIT ...

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK ...

iTeos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage trial for lung cancer. Read more here.

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of ...